good finds Thank listen and this hope and call. well of you, and Mark, families morning, you I safe as you to your everyone. this each
and employees, COVID-XX and As we pandemic, other top health partners to patients through of healthcare community our our navigate in the the priority. safety the continue remain
We have strict protocols, across sites these our emerging vigilant monitoring as pandemic, information have managed safety our effectively. around well of protocols as have prevention. transmission in and business place virus the operations in start we Since been
workers to manufactured essential as our products Our have and continuously on remained shipped we customers. our campus
we our continued other to plan to remotely and Our thoughtful safe place work ensures employees return and employees in campuses. of different have that our a return-to-office the
or a Lantheus, be We best-in-class this impressed radiopharmaceuticals has and We in would with didn't and market That the believe our patient strategic team franchise. build Lantheus AI, beginning each of the acceleration artificial offerings and precision and to at pharma opportunities and analytics be ensure and the dedication we capabilities both members in deliver milestones are manufacturing In to the we to of the product out At with outset, organization and closing commitment Lantheus for new portfolios begin I include chapter been our and been not our will in the complementary intelligence ensure other process, of vision. the both of my the pleased can intent serve. with we complement acquisition. demand, companies, of believe target strengths the Since we demand oncology near Progenics we effort serve milestones but PyL submission virtual, the to changed, and additional microbubble represents the ensure and goal our term, plan our will by diagnostics, Progenics. NDA has the integration AZEDRA meet the services. that from to awareness specialty our imagine have of markets next this so
deal capitalize The have Life we on leading use Now and this are to moved value close be with continues to creation. to field. of in for excited both beyond opportunities integration, Science evolve in intend to emerging isotopes we company diagnostic that applications, we the sector a
the and completion the marriage More we acquisition, a treatment. healthcare positioned important serve importantly, of with well this to of more community are diagnosis believe with we the goal,
that offering represented therapeutics, and improves to is believe will be companion in to radioisotopes and diagnostics, valued as physicians, and patient developing this services. a theragnostics radioisotope-related of lead payers. goal and pharma companion analytics principles management outcomes patients by landscape therapeutic Our as AI the We diagnostics, with well paired and
seen number elective Now, hospitals of of as in discuss quarter. of first intended the of anticipated as the saving to the guidance our will patients, trends the commercialized performed half latter more to we our of will business. impact treatment our limit impact that procedures and discussing in early pipeline. of we starting the latter infected time, typically before our the of second-quarter measures spread a Accordingly, correctly we that the result business announced COVID-XX the be the March, on impact mitigate cost the the to COVID-XX our portfolio, restricted business in suspended April, of announced on for are instead for COVID-XX recognized part of At declining In economic I significant than demand products, our and pandemic access infection a we focused outpatients. pandemic, that
diagnostic enter our experienced steady shaped the applicable the restoration patient's As regional and diagnostic impacted during of has DEFINITY procedures ultrasound, areas because the most the infectious equipment which procedure to the for patients trends, ill that a where use chosen outpatient feedback modality, stationary business. diagnostic for than hospitals of suggests setting inpatient the however been safety this increased This and access willingness at in to use including of Anecdotal rather hospitals to convenience potentially transport been second ultrasound they of Noteworthy of performed patients diagnostic located. we within time. recovery the disease need by very bedside recovery is been hospitals of to the of trend having and of the services. quarter have progressed, has
sales enhancing programs. team DEFINITY. such working the by and increased has this of of sales period, have where While remotely information during was this customers as our use believe, relative been in our training additional driven period, the we agent ultrasound an ultrasound use virtual we DEFINITY strength provided and of through appropriate, engaged regularly and The
individual insight the use level. to start and to during of business in benefit to These commonly strong environment. Because this demonstrated procedures us year delivered of our greater sales about pandemic, the pandemic. Therefore, the the commercialized impact of give current does elective than data have the a access more directly the the sight in had products healthy at for even Our pandemic. products DEFINITY has DEFINITY-related market XXXX, procedures trend the of we DEFINITY our planning normally, for hospital in been we've throughout diagnostic great analyses Having microbubble data. the cited so return broader the franchise. metric our prior direct to sell customer to line hospitals, onset we of a
DEFINITY noteworthy hospital the they to any field-based customers products pandemic, point of think use is or other settings. available we employees safe nuclear in it assist were during did in also share not to ensure that understanding of I to the at our our our furlough any and
offering their regions. and assess been needs. This been during As our also particular with able in to additional has services have been paused continuously returned preparation pandemic outpatient acute customers period the we to such, that have the in most guided and our regular of hospitals contact information for had as
was merger soon had completion completed. been our prior AZEDRA we of with the activities furloughed, those employees the customer-related the employees as to as and Progenics, While reinstated their field-based merger
import application and We in stakeholders license quarter to other healthcare clinicians, business, an filed we drug collectively our facing our shared on are that I pandemic supporting committed other us. physicians to respect needs as we developments in to with We earnings important patients, and fight is this in the their believe Product to reviewed. With by milestone DEFINITY the an first with the DEFINITY call, accepted Medical efforts I National was indications. China for that an application am our or being China. in now NMPA, commercialize report our NMPA the is pleased Administration echocardiography our
the Regarding not the have potential generic a filed notice received application. U.S. in status ANDA to-date DEFINITY, of market we an of to
intellectual we DEFINITY noted to in microbubble our the and growth believe prospects franchise. have remain our property for defend before, As estate I've we confident plans continued
challenges required at relatively most one in logistics performed quarter. also in during receive suppliers, of manufacturing that early our business despite to well core supply pandemic-related, our competencies TechneLite quarter. moly able the Lantheus. second These were We our notably the complications airline with from were schedules, flexibility Our
impacted. manufacturing I through. stakeholder generation Our for demand did minimally facing since job a fantastic that to pull logistics Relating the field-based the were intent, teams an of and announced Progenics to been and we customers structure ensure acquisition, our has AZEDRA, would it undertake to first assessment to opportunities optimize patient note that
the those While noted, on of paused, we newly day-one were merged field-based demand previously reinstated company. creating efforts employees as Progenics I by
are quarters. FDA-approved reengage commercial implementing we be As are committed We footprint only this over customers, and stakeholders strategies the ensuring treatment. and and paraganglioma therapy our feel opportunity pheochromocytomas with market of we sales to for medical important to patients and teams these several address have PPGL, aware patient-related and or next medical and these will certain we exists access believe the to other for
with with have progress Moving visualize prostate our our XXXX, American onto Medicine recurrent Nuclear tissue PET cancer Society were important measured trial prostate agent metastases we ASCO, our is recently men and bone Molecular as recurrence PyL and or of cancer. prostate from biochemical product toward added pipeline. clinicians results candidates, that SNMMI. cancer and the or metastatic discuss of Imaging I both uninformative our PSMA submission. CONDOR performance internal diagnostic imaging merger trial endpoint primary targeted pivotal term new of advanced pipeline, imaging biochemical as registrational in enables locally to on with based cancer will NDA and agent, Society diagnostic Clinical the patients of prostate baseline therapeutic PyL in own two PyL modalities. positive opportunities men of Today, and The as our completed, two conventional in nearest and/or Progenics the with presented PyL at III Phase Oncology and recurrent The a CONDOR the soft well our our in meetings,
data, the in endpoint data disease trial, patients CONDOR based the CONDOR disease physicians in physicians' of the a was trial, also management the modify change endpoint, imaging addition patients. they to presented PyL indicated intent the presented In goal plan secondary treatment on inform PyL results. the the in for non-invasively with Importantly, the key for and one for were SNMMI, primary presented they in plan management growing XX.X% ASCO at which cancer would most potential physicians highlight These and planning of U.S. of prostate the the reliably, during ultimate the cancer both and forms detect better of disease of in prevalent men. improving management in to and
PET related and product Our clinical a data pumps the with of July PYL issue, We related the the issue trial. team not This in impact equipment manufacturing in of could FDA. NDA on were has working PyL at production drug which channel been the manufacturing the partner potential of any facilities to diligently PMF. our to the equipment-related in or the informed early the is
are We NDA fourth that have filing filing PyL's to priority time the top the moved the different target later can already are issue out a and mediation assessed we team potential accelerate than remains building The to filing. believe continually our middle the efficiencies will support assessing no date the quarter. timeline for NDA are and we that and of Simultaneously, launch. our addressing
XX F informed Phase our and cardiac or partner III agent, GE imaging Flurpiridaz PET that commercialization to us has trial Healthcare novel now second Turning development continues.
the by mid-XXXX, of that, intends the approval, enrollment and key However, to to expect With this new complete Healthcare Bob. been impact due I over to Bob? update and call pandemic. XXXX. on will resume early assuming delayed in GE regulatory my the programs strategic has commercialization and turn in commercial enrollment begin to enrollment conclude and patient quarter
